Share Price and Basic Stock Data
Last Updated: November 14, 2025, 11:32 pm
| PEG Ratio | 1.15 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Choksi Laboratories Ltd, operating in the Medical Research Services sector, reported a market capitalization of ₹99.8 Cr and a share price of ₹143. The company’s revenue from operations has shown a robust upward trajectory, with sales rising from ₹30.04 Cr in FY 2022 to an estimated ₹41.78 Cr in FY 2025. This represents a compound annual growth rate (CAGR) of approximately 17.4%, reflecting the company’s strong position in a growing industry. Quarterly sales figures also indicate fluctuations, with the highest recorded sales of ₹11.40 Cr in March 2025 and a quarterly low of ₹7.84 Cr in December 2022. The operational performance is further supported by an operating profit margin (OPM) of 30.70%, indicating efficient cost management amidst rising revenues. Choksi’s sales strategy appears to capitalize on both domestic and international markets, contributing to its revenue growth amidst competitive pressures in the medical research sector.
Profitability and Efficiency Metrics
Choksi Laboratories has displayed commendable profitability metrics, with a net profit of ₹1.50 Cr and a net profit margin of 3.64% for FY 2025. The company’s return on equity (ROE) stood at 6.63%, while the return on capital employed (ROCE) recorded a slightly higher figure of 9.20%. These figures are indicative of Choksi’s ability to generate returns for shareholders, albeit at rates lower than some industry benchmarks. The interest coverage ratio (ICR) of 4.27x suggests that the company can comfortably meet its interest obligations, reinforcing financial stability. However, the cash conversion cycle (CCC) of -474.95 days raises concerns regarding liquidity management, indicating potential inefficiencies in inventory management and collection processes. The operating profit has generally remained stable, with an OPM of 30.70% showcasing operational efficiency, although quarterly fluctuations may impact overall profitability.
Balance Sheet Strength and Financial Ratios
Choksi Laboratories’ balance sheet reveals a mixed financial position with total borrowings of ₹29.15 Cr against reserves of ₹16.64 Cr, highlighting a reliance on debt financing. The debt-to-equity ratio stood at 1.19, indicating a relatively leveraged position compared to industry norms, which may pose risks in a rising interest rate environment. However, the company has maintained a book value per share of ₹33.89, reflecting a solid asset base. The current ratio of 0.68 suggests potential liquidity issues, as it is below the ideal benchmark of 1.0, indicating that current liabilities exceed current assets. Additionally, the asset turnover ratio of 0.65 implies that Choksi is generating ₹0.65 in revenue for every ₹1 of assets, which is moderately efficient. The company’s ability to manage its liabilities in relation to its assets will be crucial for sustaining growth and stability in the forthcoming fiscal periods.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Choksi Laboratories indicates a stable ownership structure, with promoters holding 31.48% of the equity. Foreign institutional investors (FIIs) have recently increased their stake to 5.69%, reflecting growing interest from foreign investors in the company. The public holds a significant 62.83% stake, which indicates broad retail investor participation. The number of shareholders has gradually increased from 3,518 in December 2022 to 4,067 by March 2025, suggesting enhanced investor confidence and interest in the company’s prospects. However, the lack of domestic institutional investor (DII) participation could pose challenges in terms of stability during market fluctuations. The steady promoter holding and rising FII stakes could signal a positive outlook for Choksi, provided the company continues to improve its operational and financial metrics to attract further institutional investment.
Outlook, Risks, and Final Insight
Choksi Laboratories is positioned for growth, driven by increasing revenues and a stable operational framework. However, the company faces risks related to high leverage and potential liquidity challenges, evidenced by a current ratio of 0.68 and a debt-to-equity ratio of 1.19. The volatility in quarterly sales and the negative cash conversion cycle further complicate the outlook. As the company navigates these challenges, it must enhance operational efficiencies and focus on liquidity management to sustain its growth trajectory. Should Choksi successfully address these risks and maintain its revenue momentum, it could solidify its market position and attract greater institutional investment. Conversely, failure to manage its leverage and liquidity could hinder growth and investor confidence in a competitive landscape. The coming fiscal years will be critical in determining Choksi’s ability to capitalize on its strengths while mitigating inherent risks.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Choksi Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 97.6 Cr. | 140 | 237/59.2 | 58.8 | 33.9 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,845 Cr. | 639 | 903/358 | 38.1 | 93.5 | 0.16 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,845.00 Cr | 389.50 | 48.45 | 63.70 | 0.08% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.14 | 8.24 | 8.68 | 7.84 | 9.78 | 8.88 | 7.95 | 8.79 | 11.12 | 10.74 | 9.26 | 10.38 | 11.40 |
| Expenses | 5.44 | 5.95 | 6.35 | 5.61 | 6.30 | 6.45 | 5.84 | 6.55 | 7.63 | 7.91 | 6.90 | 7.84 | 7.90 |
| Operating Profit | 4.70 | 2.29 | 2.33 | 2.23 | 3.48 | 2.43 | 2.11 | 2.24 | 3.49 | 2.83 | 2.36 | 2.54 | 3.50 |
| OPM % | 46.35% | 27.79% | 26.84% | 28.44% | 35.58% | 27.36% | 26.54% | 25.48% | 31.38% | 26.35% | 25.49% | 24.47% | 30.70% |
| Other Income | 0.02 | 0.00 | 0.02 | 0.10 | 2.26 | 0.00 | 0.05 | 0.00 | 0.06 | 0.01 | 0.01 | 0.01 | 0.04 |
| Interest | 0.76 | 0.75 | 0.87 | 0.93 | 0.94 | 0.82 | 0.74 | 0.67 | 0.77 | 0.72 | 0.66 | 0.69 | 0.58 |
| Depreciation | 1.35 | 1.40 | 1.31 | 1.36 | 1.42 | 1.39 | 1.41 | 1.43 | 1.49 | 1.50 | 1.61 | 1.68 | 1.70 |
| Profit before tax | 2.61 | 0.14 | 0.17 | 0.04 | 3.38 | 0.22 | 0.01 | 0.14 | 1.29 | 0.62 | 0.10 | 0.18 | 1.26 |
| Tax % | 14.18% | -107.14% | 64.71% | 425.00% | 11.54% | -59.09% | 0.00% | 57.14% | 46.51% | 30.65% | 20.00% | 44.44% | 26.98% |
| Net Profit | 2.24 | 0.30 | 0.06 | -0.13 | 2.99 | 0.36 | 0.01 | 0.06 | 0.68 | 0.42 | 0.08 | 0.11 | 0.92 |
| EPS in Rs | 3.22 | 0.43 | 0.09 | -0.19 | 4.29 | 0.52 | 0.01 | 0.09 | 0.98 | 0.60 | 0.11 | 0.16 | 1.32 |
Last Updated: July 16, 2025, 10:25 am
Below is a detailed analysis of the quarterly data for Choksi Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 11.40 Cr.. The value appears strong and on an upward trend. It has increased from 10.38 Cr. (Dec 2024) to 11.40 Cr., marking an increase of 1.02 Cr..
- For Expenses, as of Mar 2025, the value is 7.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.84 Cr. (Dec 2024) to 7.90 Cr., marking an increase of 0.06 Cr..
- For Operating Profit, as of Mar 2025, the value is 3.50 Cr.. The value appears strong and on an upward trend. It has increased from 2.54 Cr. (Dec 2024) to 3.50 Cr., marking an increase of 0.96 Cr..
- For OPM %, as of Mar 2025, the value is 30.70%. The value appears strong and on an upward trend. It has increased from 24.47% (Dec 2024) to 30.70%, marking an increase of 6.23%.
- For Other Income, as of Mar 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Dec 2024) to 0.58 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Mar 2025, the value is 1.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.68 Cr. (Dec 2024) to 1.70 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Dec 2024) to 1.26 Cr., marking an increase of 1.08 Cr..
- For Tax %, as of Mar 2025, the value is 26.98%. The value appears to be improving (decreasing) as expected. It has decreased from 44.44% (Dec 2024) to 26.98%, marking a decrease of 17.46%.
- For Net Profit, as of Mar 2025, the value is 0.92 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Dec 2024) to 0.92 Cr., marking an increase of 0.81 Cr..
- For EPS in Rs, as of Mar 2025, the value is 1.32. The value appears strong and on an upward trend. It has increased from 0.16 (Dec 2024) to 1.32, marking an increase of 1.16.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.16 | 24.45 | 25.10 | 28.63 | 30.40 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.70 | 41.78 | 44.14 |
| Expenses | 17.85 | 19.30 | 19.95 | 23.85 | 24.06 | 26.48 | 24.62 | 21.57 | 21.14 | 24.17 | 26.42 | 30.48 | 32.27 |
| Operating Profit | 4.31 | 5.15 | 5.15 | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.90 | 10.27 | 10.28 | 11.30 | 11.87 |
| OPM % | 19.45% | 21.06% | 20.52% | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 27.05% | 26.89% |
| Other Income | 0.10 | 0.63 | -0.05 | 0.86 | 0.35 | 0.25 | -2.80 | 0.49 | 0.12 | 2.47 | 0.16 | 0.07 | 0.06 |
| Interest | 1.19 | 1.57 | 1.23 | 1.47 | 1.59 | 1.54 | 1.89 | 2.82 | 3.23 | 3.52 | 3.06 | 2.72 | 2.56 |
| Depreciation | 1.59 | 2.83 | 2.73 | 2.86 | 3.16 | 3.68 | 4.56 | 4.60 | 5.43 | 5.50 | 5.71 | 6.50 | 6.75 |
| Profit before tax | 1.63 | 1.38 | 1.14 | 1.31 | 1.94 | 2.29 | -5.71 | -2.81 | 0.36 | 3.72 | 1.67 | 2.15 | 2.62 |
| Tax % | 28.83% | 36.23% | 36.84% | 32.06% | 29.90% | 30.13% | -32.05% | -7.12% | 44.44% | 13.71% | 32.93% | 29.30% | |
| Net Profit | 1.17 | 0.88 | 0.72 | 0.89 | 1.35 | 1.60 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | 1.66 |
| EPS in Rs | 1.68 | 1.26 | 1.03 | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 | 2.38 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.79% | -18.18% | 23.61% | 51.69% | 18.52% | -342.50% | 32.73% | 108.05% | 1428.57% | -65.42% | 36.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | 6.60% | 41.79% | 28.07% | -33.17% | -361.02% | 375.23% | 75.31% | 1320.53% | -1493.99% | 102.36% |
Choksi Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 32% |
| 3 Years: | 93% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 83% |
| 3 Years: | 86% |
| 1 Year: | 175% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 117.27 | 126.15 | 124.77 | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 |
| Days Payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | |||
| Cash Conversion Cycle | 117.27 | 126.15 | 124.77 | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 |
| Working Capital Days | 8.73 | 29.26 | 3.34 | -23.71 | -18.37 | 28.02 | 21.13 | -49.73 | -23.33 | 11.66 | -49.13 | -71.29 |
| ROCE % | 9.25% | 7.94% | 7.51% | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Diluted EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Cash EPS (Rs.) | 11.52 | 9.80 | 12.50 | 8.09 | 2.86 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Revenue From Operations / Share (Rs.) | 59.99 | 52.68 | 49.45 | 43.13 | 36.88 |
| PBDIT / Share (Rs.) | 16.23 | 14.90 | 15.01 | 12.93 | 6.62 |
| PBIT / Share (Rs.) | 6.89 | 6.70 | 7.12 | 5.13 | 0.01 |
| PBT / Share (Rs.) | 3.09 | 2.39 | 5.34 | 0.52 | -4.03 |
| Net Profit / Share (Rs.) | 2.19 | 1.59 | 4.61 | 0.29 | -3.74 |
| PBDIT Margin (%) | 27.04 | 28.29 | 30.35 | 29.97 | 17.95 |
| PBIT Margin (%) | 11.49 | 12.72 | 14.39 | 11.90 | 0.03 |
| PBT Margin (%) | 5.15 | 4.53 | 10.80 | 1.22 | -10.93 |
| Net Profit Margin (%) | 3.64 | 3.02 | 9.32 | 0.68 | -10.15 |
| Return on Networth / Equity (%) | 6.45 | 4.99 | 15.20 | 1.15 | -14.69 |
| Return on Capital Employeed (%) | 11.58 | 10.83 | 10.36 | 7.31 | 0.02 |
| Return On Assets (%) | 2.33 | 1.79 | 5.31 | 0.32 | -3.92 |
| Long Term Debt / Equity (X) | 0.64 | 0.81 | 1.12 | 1.54 | 1.77 |
| Total Debt / Equity (X) | 1.19 | 1.32 | 1.44 | 1.94 | 1.91 |
| Asset Turnover Ratio (%) | 0.65 | 0.59 | 0.55 | 0.45 | 0.39 |
| Current Ratio (X) | 0.68 | 0.77 | 1.11 | 0.90 | 0.80 |
| Quick Ratio (X) | 0.66 | 0.75 | 1.10 | 0.88 | 0.79 |
| Inventory Turnover Ratio (X) | 90.75 | 8.94 | 9.63 | 10.95 | 17.75 |
| Interest Coverage Ratio (X) | 4.27 | 3.45 | 2.99 | 2.81 | 1.64 |
| Interest Coverage Ratio (Post Tax) (X) | 1.57 | 1.37 | 1.27 | 1.06 | 0.07 |
| Enterprise Value (Cr.) | 111.15 | 58.14 | 53.31 | 52.04 | 39.01 |
| EV / Net Operating Revenue (X) | 2.66 | 1.58 | 1.55 | 1.73 | 1.52 |
| EV / EBITDA (X) | 9.84 | 5.60 | 5.10 | 5.78 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| Price / BV (X) | 3.55 | 1.33 | 1.10 | 0.98 | 0.30 |
| Price / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| EarningsYield | 0.01 | 0.03 | 0.13 | 0.01 | -0.47 |
After reviewing the key financial ratios for Choksi Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.52. This value is within the healthy range. It has increased from 9.80 (Mar 24) to 11.52, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 59.99. It has increased from 52.68 (Mar 24) to 59.99, marking an increase of 7.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.23. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 16.23, marking an increase of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 6.89. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 6.89, marking an increase of 0.19.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.09. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 3.09, marking an increase of 0.70.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.19. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For PBDIT Margin (%), as of Mar 25, the value is 27.04. This value is within the healthy range. It has decreased from 28.29 (Mar 24) to 27.04, marking a decrease of 1.25.
- For PBIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has decreased from 12.72 (Mar 24) to 11.49, marking a decrease of 1.23.
- For PBT Margin (%), as of Mar 25, the value is 5.15. This value is below the healthy minimum of 10. It has increased from 4.53 (Mar 24) to 5.15, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has increased from 3.02 (Mar 24) to 3.64, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 15. It has increased from 4.99 (Mar 24) to 6.45, marking an increase of 1.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 11.58, marking an increase of 0.75.
- For Return On Assets (%), as of Mar 25, the value is 2.33. This value is below the healthy minimum of 5. It has increased from 1.79 (Mar 24) to 2.33, marking an increase of 0.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.64, marking a decrease of 0.17.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has decreased from 1.32 (Mar 24) to 1.19, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has increased from 0.59 (Mar 24) to 0.65, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1.5. It has decreased from 0.77 (Mar 24) to 0.68, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.66, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 90.75. This value exceeds the healthy maximum of 8. It has increased from 8.94 (Mar 24) to 90.75, marking an increase of 81.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.27. This value is within the healthy range. It has increased from 3.45 (Mar 24) to 4.27, marking an increase of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.37 (Mar 24) to 1.57, marking an increase of 0.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111.15. It has increased from 58.14 (Mar 24) to 111.15, marking an increase of 53.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.66, marking an increase of 1.08.
- For EV / EBITDA (X), as of Mar 25, the value is 9.84. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 9.84, marking an increase of 4.24.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For Price / BV (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 3.55, marking an increase of 2.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Choksi Laboratories Ltd:
- Net Profit Margin: 3.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.58% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.45% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 58.8 (Industry average Stock P/E: 48.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.64%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Survey No 9/1, Near Tulsiyana Industrial Park, Indore Madhya Pradesh 453555 | compliance_officer@choksilab.com www.choksilab.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sunil Choksi | Managing Director |
| Mrs. Stela Choksi | Whole Time Director |
| Ms. Himika Choksi | Whole Time Director |
| Mr. Vyangesh Choksi | Whole Time Director |
| Mr. Raghmendra Singh | Independent Director |
| Mrs. Meenaxi Patidar | Independent Director |
| Mrs. Prachi Mantri | Independent Director |
| Mrs. Abha Shastri | Independent Director |